出版：Market Research Future（マーケットリサーチフューチャー） 出版年月：2022年12月
Heart Tumor Market Research Report – Forecast till 2030
心臓腫瘍市場調査レポート : 2030 年までの予測
| ページ数 | 137 |
| 価格 | |
| シングルユーザライセンス | USD4,950 |
| エンタープライズライセンス | USD7,250 |
| 種別 | 英文調査報告書 |
Heart Tumor Market Research Report – Forecast till 2030
Market Overview
The Heart Tumor Market is anticipated to register a significant CAGR of 6.31% during the forecast period owing to the market value of USD 783.34 million in 2021. A cardiac tumor is an abnormal development of the heart that can be either cancerous (malignant) or non-cancerous. Primary (arising from the heart itself) and secondary cardiac tumors are further classifications for the disease. A primary heart tumor only affects about 1 in 3000 persons, making it incredibly rare. 20–30 times more often than the main cardiac tumor, the secondary cardiac tumor typically arises in patients with lung cancer, breast cancer, melanoma, renal cell carcinoma, or lymphoma.
The market is fueled by variables such as the rising incidence of cardiac tumors, the rising financing and quantity of cancer research projects, and the rising number of strategic initiatives. However, it is projected that expanding efforts by public and private organizations to raise awareness about heart tumors would present profitable prospects for market participants. The development of the heart tumor market, however, may be constrained by a lack of public knowledge and a shortage of radiologists with the necessary skills. One of the key drivers propelling the heart tumor market is the rising prevalence of heart tumors, including cardiac sarcoma, arrhythmia, chest discomfort, stroke, and pericardial effusion. Additionally, rising asymptomatic carriers and rising cardiac sarcoma rates, particularly during the COVID-19 pandemic, have further fueled the market expansion.
Segment Overview
Global Heart Tumor Market is divided based on Tumor Type and Diagnosis & Treatment. Based on the tumor type the market is bifurcated into Primary Tumor and Secondary Tumor. By Diagnosis & Treatment, the market is divided into Diagnosis and Treatment. The diagnosis segment is further categorized into CT scan, MRI Scan, Nuclear Imaging, Echocardiography, and Others. Whereas the treatment type is further classified into Surgery, Chemotherapy, Radiotherapy, and Others.
Regional Analysis
Based on region, North America had the greatest market share, or 40.72%, and is expected to rule the global market for heart tumors over the projection period. North America includes the United States and Canada. In 2021, North America accounted for the greatest market share. This is because of things like the widespread usage of cardiac biopsies and the high incidence of PCTs. Primary Malignant Cardiac Tumors (PMCTs), a subset of Primary Cardiac Tumors (PCTs), are more common in North America and Europe than in other countries, which is supporting the market for heart tumors. Over the projected period, Asia-Pacific is expected to have the greatest CAGR, at 8.06%. This is because of elements like the presence off a few critical organizations and they are effectively money management and extending through acquisitions, consolidations, development, and item dispatches in the locale.
Major Players
The prominent players in the heart Tumor market include Boston Scientific Corporation (US), FUJIFILM Corporation (Japan), GE Healthcare (US), Siemens (Germany), Amneal Pharmaceuticals llc (US), Shimadzu Corporation (Japan), TomTec Imaging Systems GmbH (Germany), Koninklijke Philips N.V (The Netherlands), Toshiba Corporation (Japan), and Terumo cardiovascular systems corporation (US).
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 LIST OF ASSUMPTIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 GROWING PREVALENCE OF CARDIAC TUMORS
4.2.2 INCREASING NUMBER OF CANCER RESEARCH AND FUNDING
4.2.3 RISING NUMBER OF STRATEGIC INITIATIVES
4.3 RESTRAINTS
4.3.1 LACK OF AWARENESS AMONG PEOPLE
4.3.2 LACK OF SKILLED RADIOLOGISTS
4.4 OPPORTUNITIES
4.4.1 INCREASING INITIATIVES BY PUBLIC AND PRIVATE ORGANIZATIONS TO DRIVE AWARENESS REGARDING HEART TUMOR
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE HEART TUMOR MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTION
5.3.3 IMPACT ON KEY PLAYERS
5.3.4 IMPACT ON REGION
6 GLOBAL HEART TUMOR MARKET, TUMOR TYPE
6.1 OVERVIEW
6.2 PRIMARY TUMOR
6.3 SECONDARY TUMOR
7 GLOBAL HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT
7.1 OVERVIEW
7.2 DIAGNOSIS
7.2.1 CT SCAN
7.2.2 MRI SCAN
7.2.3 NUCLEAR IMAGING
7.2.4 ECHOCARDIOGRAPHY
7.2.5 OTHERS
7.3 TREATMENT
7.3.1 COST PER PROCEDURE
7.3.2 SURGERY
7.3.3 CHEMOTHERAPY
7.3.4 RADIOTHERAPY
7.3.5 OTHERS
8 GLOBAL HEART TUMOR MARKET, BY REGION
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 GERMANY
8.3.2 UK
8.3.3 FRANCE
8.3.4 ITALY
8.3.5 SPAIN
8.3.6 REST OF EUROPE
8.4 ASIA-PACIFIC
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 AUSTRALIA
8.4.5 SOUTH KOREA
8.4.6 REST OF ASIA-PACIFIC
8.5 REST OF THE WORLD
8.5.1 MIDDLE EAST
8.5.2 AFRICA
8.5.3 LATIN AMERICA
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPETITIVE BENCHMARKING
9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL HEART TUMOR MARKET
9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL HEART TUMOR MARKET
9.5 KEY DEVELOPMENT ANALYSIS
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
9.6.2 PARTERSHIP/AGREEMENT
9.6.3 MERGER /ACQUISTION
9.6.4 EXPANSION /INVESTMENT
9.7 FINANCIAL MATRIX
9.7.1 SALES (USD MILLION), 2021
9.7.2 R&D EXPENDITURE (USD MILLION), 2021
10 COMPANY PROFILE
10.1 KONINKLIJKE PHILIPS N.V.
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 PRODUCTS/SERVICES OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 FUJIFILM CORPORATION
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCTS OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 KEY STRATEGIES
10.3 GE HEALTHCARE
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.3.6 KEY STRATEGIES
10.4 SIEMENS
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIES
10.5 AMNEAL PHARMACEUTICALS LLC
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIES
10.6 SHIMADZU CORPORATION
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 TOMTEC IMAGING SYSTEMS GMBH
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIES
10.8 TOSHIBA CORPORATION
10.8.1 COMPANY OVERVIEWS
10.8.2 FINANCIAL OVERVIEW
10.8.3 PRODUCTS TOSHIBA CORPORATION OFFERED
10.8.4 KEY DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.8.6 KEY STRATEGIES
10.9 BOSTON SCIENTIFIC CORPORATION
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIES
10.10 TERUMO CARDIOVASCULAR SYSTEMS CORPORATION
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIES
11 APPENDIX
11.1 REFERENCES
11.2 RELATED REPORTS
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
TABLE 2 GLOBAL: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 3 GLOBAL: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 4 GLOBAL: HEART TUMOR MARKET, FOR PRIMARY TUMOR, BY REGION, 2018–2030 (USD MILLION)
TABLE 5 GLOBAL: HEART TUMOR MARKET, FOR PRIMARY TUMOR, BY REGION, 2018–2030 (CYCLES)
TABLE 6 GLOBAL: HEART TUMOR MARKET, FOR SECONDARY TUMOR, BY REGION, 2018–2030 (USD MILLION)
TABLE 7 GLOBAL: HEART TUMOR MARKET, FOR SECONDARY TUMOR, BY REGION, 2018–2030 (CYCLES)
TABLE 8 GLOBAL: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 9 GLOBAL: HEART TUMOR MARKET, FOR DIAGNOSIS, BY REGION, 2018–2030 (USD MILLION)
TABLE 10 GLOBAL: HEART TUMOR MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)
TABLE 11 GLOBAL: HEART TUMOR MARKET, FOR CT SCAN, BY REGION, 2018–2030 (USD MILLION)
TABLE 12 GLOBAL: HEART TUMOR MARKET, FOR MRI SCAN, BY REGION, 2018–2030 (USD MILLION)
TABLE 13 GLOBAL: HEART TUMOR MARKET, FOR NUCLEAR IMAGING, BY REGION, 2018–2030 (USD MILLION)
TABLE 14 GLOBAL: HEART TUMOR MARKET, FOR ECHOCARDIOGRAPHY, BY REGION, 2018–2030 (USD MILLION)
TABLE 15 GLOBAL: HEART TUMOR MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)
TABLE 16 GLOBAL AVERAGE SELLING PRICE (ASP) FOR HEART TUMOR TREATMENT (USD)
TABLE 17 GLOBAL: HEART TUMOR MARKET, FOR TREATMENT, BY REGION, 2018–2030 (USD MILLION)
TABLE 18 GLOBAL: HEART TUMOR MARKET, FOR TREATMENT, BY TYPE, 2018–2030 (USD MILLION)
TABLE 19 GLOBAL: HEART TUMOR MARKET, FOR TREATMENT, BY TYPE, 2018–2030 (CYCLES)
TABLE 20 GLOBAL: HEART TUMOR MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)
TABLE 21 GLOBAL: HEART TUMOR MARKET, FOR SURGERY, BY REGION, 2018–2030 (CYCLES)
TABLE 22 GLOBAL: HEART TUMOR MARKET, FOR CHEMOTHERAPY, BY REGION, 2018–2030 (USD MILLION)
TABLE 23 GLOBAL: HEART TUMOR MARKET, FOR CHEMOTHERAPY, BY REGION, 2018–2030 (CYCLES)
TABLE 24 GLOBAL: HEART TUMOR MARKET, FOR RADIOTHERAPY, BY REGION, 2018–2030 (USD MILLION)
TABLE 25 GLOBAL: HEART TUMOR MARKET, FOR RADIOTHERAPY, BY REGION, 2018–2030 (CYCLES)
TABLE 26 GLOBAL: HEART TUMOR MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)
TABLE 27 GLOBAL: HEART TUMOR MARKET, FOR OTHERS, BY REGION, 2018–2030 (CYCLES)
TABLE 28 GLOBAL HEART TUMOR MARKET, BY REGION, 2018–2030 (USD MILLION)
TABLE 29 GLOBAL HEART TUMOR MARKET, BY REGION, 2018–2030 (CYCLES)
TABLE 30 NORTH AMERICA: HEART TUMOR MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 31 NORTH AMERICA: HEART TUMOR MARKET, BY COUNTRY, 2018–2030 (CYCLES)
TABLE 32 NORTH AMERICA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 33 NORTH AMERICA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 34 NORTH AMERICA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 35 NORTH AMERICA: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 36 NORTH AMERICA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 37 NORTH AMERICA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 38 US: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 39 US: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 40 US: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 41 US: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 42 US: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 43 US: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 44 CANADA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 45 CANADA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 46 CANADA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 47 CANADA: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 48 CANADA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 49 CANADA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 50 EUROPE: HEART TUMOR MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 51 EUROPE: HEART TUMOR MARKET, BY COUNTRY, 2018–2030 (CYCLES)
TABLE 52 EUROPE: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 53 EUROPE: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 54 EUROPE: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 55 EUROPE: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 56 EUROPE: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 57 EUROPE: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 58 GERMANY: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 59 GERMANY: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 60 GERMANY: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 61 GERMANY: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 62 GERMANY: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 63 GERMANY: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 64 UK: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 65 UK: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 66 UK: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 67 UK: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 68 UK: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 69 UK: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 70 FRANCE: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 71 FRANCE: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 72 FRANCE: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 73 FRANCE: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 74 FRANCE: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 75 FRANCE: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 76 ITALY: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 77 ITALY: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 78 ITALY: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 79 ITALY: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 80 ITALY: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 81 ITALY: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 82 SPAIN: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 83 SPAIN: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 84 SPAIN: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 85 SPAIN: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 86 SPAIN: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 87 SPAIN: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 88 REST OF EUROPE: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 89 REST OF EUROPE: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 90 REST OF EUROPE: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 91 REST OF EUROPE: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 92 REST OF EUROPE: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 93 REST OF EUROPE: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 94 ASIA-PACIFIC: HEART TUMOR MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 95 ASIA-PACIFIC: HEART TUMOR MARKET, BY COUNTRY, 2018–2030 (CYCLES)
TABLE 96 ASIA-PACIFIC: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 97 ASIA-PACIFIC: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 98 ASIA-PACIFIC: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 99 ASIA-PACIFIC: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 100 ASIA-PACIFIC: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 101 ASIA-PACIFIC: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 102 JAPAN: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 103 JAPAN: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 104 JAPAN: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 105 JAPAN: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 106 JAPAN: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 107 JAPAN: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 108 CHINA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 109 CHINA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 110 CHINA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 111 CHINA: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 112 CHINA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 113 CHINA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 114 INDIA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 115 INDIA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 116 INDIA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 117 INDIA: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 118 INDIA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 119 INDIA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 120 AUSTRALIA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 121 AUSTRALIA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 122 AUSTRALIA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 123 AUSTRALIA: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 124 AUSTRALIA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 125 AUSTRALIA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 126 SOUTH KOREA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 127 SOUTH KOREA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 128 SOUTH KOREA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 129 SOUTH KOREA: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 130 SOUTH KOREA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 131 SOUTH KOREA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 132 REST OF ASIA-PACIFIC: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 133 REST OF ASIA-PACIFIC: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 134 REST OF ASIA-PACIFIC: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 135 REST OF ASIA-PACIFIC: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 136 REST OF ASIA-PACIFIC: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 137 REST OF ASIA-PACIFIC: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 138 REST OF THE WORLD: HEART TUMOR MARKET, BY COUNTRY, 2018–2030 (USD MILLION)
TABLE 139 REST OF THE WORLD: HEART TUMOR MARKET, BY COUNTRY, 2018–2030 (CYCLES)
TABLE 140 REST OF THE WORLD: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 141 REST OF THE WORLD: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 142 REST OF THE WORLD: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 143 REST OF THE WORLD: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 144 REST OF THE WORLD: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 145 REST OF THE WORLD: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 146 MIDDLE EAST: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 147 MIDDLE EAST: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 148 MIDDLE EAST: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 149 MIDDLE EAST: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 150 MIDDLE EAST: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 151 MIDDLE EAST: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 152 AFRICA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 153 AFRICA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 154 AFRICA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 155 AFRICA: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 156 AFRICA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 157 AFRICA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 158 LATIN AMERICA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (USD MILLION)
TABLE 159 LATIN AMERICA: HEART TUMOR MARKET, BY TUMOR TYPE, 2018–2030 (CYCLES)
TABLE 160 LATIN AMERICA: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)
TABLE 161 LATIN AMERICA: HEART TUMOR MARKET, BY DIAGNOSIS, 2018–2030 (USD MILLION)
TABLE 162 LATIN AMERICA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (USD MILLION)
TABLE 163 LATIN AMERICA: HEART TUMOR MARKET, BY TREATMENT, 2018–2030 (CYCLES)
TABLE 164 MAJOR PLAYERS IN THE GLOBAL HEART TUMOR MARKET
TABLE 165 MOST ACTIVE PLAYER IN THE GLOBAL HEART TUMOR MARKET
TABLE 166 PRODUCT LAUNCH/ PRODUCT APPROVAL
TABLE 167 PARTERSHIP/AGREEMENT
TABLE 168 MERGER/ACQUISTION
TABLE 169 EXPANSION/INVESTMENT
TABLE 170 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED
TABLE 171 KONINKLIJKE PHILIPS N.V.: KEY DEVELOPMENTS
TABLE 172 FUJIFILM CORPORATION: PRODUCTS OFFERED
TABLE 173 FUJIFILM CORPORATION: KEY DEVELOPMENTS
TABLE 174 GE HEALTHCARE: PRODUCTS OFFERED
TABLE 175 GE HEALTHCARE: KEY DEVELOPMENTS
TABLE 176 SIEMENS: PRODUCTS OFFERED
TABLE 177 SIEMENS: KEY DEVELOPMENTS
TABLE 178 AMNEAL PHARMACEUTICALS LLC: PRODUCTS OFFERED
TABLE 179 SHIMADZU CORPORATION: PRODUCTS OFFERED
TABLE 180 SHIMADZU CORPORATION: KEY DEVELOPMENTS
TABLE 181 TOMTEC IMAGING SYSTEMS GMBH: PRODUCTS OFFERED
TABLE 182 TOSHIBA CORPORATION: PRODUCTS OFFERED
TABLE 183 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
TABLE 184 BOSTON SCIENTIFIC CORPORATION: KEY DEVELOPMENTS
TABLE 185 TERUMO CARDIOVASCULAR SYSTEMS CORPORATION: PRODUCTS OFFERED
LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS
FIGURE 2 GLOBAL HEART TUMOR MARKET STRUCTURE
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL HEART TUMOR MARKET
FIGURE 5 DRIVER IMPACT ANALYSIS
FIGURE 6 RESTRAINT IMPACT ANALYSIS
FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL HEART TUMOR MARKET
FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: GLOBAL HEART TUMOR MARKET
FIGURE 9 GLOBAL: HEART TUMOR MARKET, BY TUMOR TYPE, 2021 & 2030 (USD MILLION)
FIGURE 10 GLOBAL: HEART TUMOR MARKET, BY TUMOR TYPE, 2021 & 2030 (CYCLES)
FIGURE 11 GLOBAL: HEART TUMOR MARKET, BY DIAGNOSIS & TREATMENT, 2021 & 2030 (USD MILLION)
FIGURE 12 GLOBAL: HEART TUMOR MARKET, BY TREAMENT, 2021 & 2030 (CYCLES)
FIGURE 13 GLOBAL HEART TUMOR MARKET, BY REGION 2021 & 2030 (USD MILLION)
FIGURE 14 GLOBAL HEART TUMOR MARKET SHARE (%), BY REGION, 2021
FIGURE 15 NORTH AMERICA: HEART TUMOR MARKET SHARE (%), BY COUNTRY 2021
FIGURE 16 EUROPE: HEART TUMOR MARKET SHARE (%), BY COUNTRY 2021
FIGURE 17 ASIA-PACIFIC: HEART TUMOR MARKET SHARE, BY COUNTRY, 2021 (%)
FIGURE 18 REST OF THE WORLD: HEART TUMOR MARKET SHARE (%), BY COUNTRY, 2021
FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS
FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL HEART TUMOR MARKET
FIGURE 21 GLOBAL HEART TUMOR MARKET: COMPETITIVE LANDSCAPE
FIGURE 22 SALES 2021
FIGURE 23 R&D EXPENDITURE, 2021
FIGURE 24 KONINKLIJKE PHILIPS N.V.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 KONINKLIJKE PHILIPS N.V.: SWOT ANALYSIS
FIGURE 26 FUJIFILM CORPORATION: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 FUJIFILM CORPORATION: SWOT ANALYSIS
FIGURE 28 GE HEALTHCARE: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 GE HEALTHCARE: SWOT ANALYSIS
FIGURE 30 SIEMENS: FINANCIAL OVERVIEW
FIGURE 31 AMNEAL PHARMACEUTICALS LLC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 SHIMADZU CORPORATION: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 SHIMADZU CORPORATION: SWOT ANALYSIS
FIGURE 34 TOSHIBA CORPORATION: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 TOSHIBA CORPORATION: SWOT ANALYSIS
FIGURE 36 BOSTON SCIENTIFIC CORPORATION: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 37 TERUMO CARDIOVASCULAR SYSTEMS CORPORATION: FINANCIAL OVERVIEW SNAPSHOT